lornoxicam
Small moleculeexperimental
Lornoxicam, also known as chlortenoxicam, is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. It is available in oral and parenteral formulations. — Wikipedia
Clinical trial activity
14 trials · 32 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
2
Phase 4
4
Earliest trial started Nov 1, 2005 (NCT00293631)
Timeline
Indications
Approved for
Studied for
- Acute Coronary Syndrome · Phase 4
- Alzheimer Disease · Phase 2
- BCG Vaccine · Phase 4
- Bunion · Phase 2
- Drug Delivery Systems · Phase 4
- Fractures, Bone · Phase 1/Phase 2
- Hematopoietic Stem Cell Transplantation · Phase 4
- Hernia, Inguinal · Phase 3
- Migraine Disorders · Phase 2
- Orthopedic Procedures · Phase 2
- Pain · Phase 2
- Postoperative Pain · Phase 4
- Urinary Bladder Neoplasms · Phase 4
Mechanism of action
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O- Mol. weight
- 371.83 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLornoxicam ↗
- ChEMBLCHEMBL1569487 ↗
Also known as
- 2h-thieno(2,3-e)-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-n-2-pyridinyl-, 1,1-dioxide
- chlortenoxicam
- chlortenoxicam
- chlortenoxicam
- chlortenoxicam
- ctx
- ctx
- ctx
- lorcam
- lornoxicam
- lornoxicam
- lornoxicam
- lornoxicam
- lornoxicam
- lornoxicam
- lornoxicam
- lornoxicam
- lornoxicam
- lornoxicamum
- lornoxicamum
- ro-139297
- ro-139297
- xefo
- xefo
- xefocam
- xefocam
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03689465 | Phase 4 | Oct 1, 2018 | Southern Medical University |
| NCT03038321 | Phase 4 | Feb 1, 2017 | Mansoura University |
| NCT03780556 | N/A | Jan 2, 2016 | Ain Shams University |
| NCT02750917 | Phase 3 | Sep 1, 2014 | Foisor Orthopedics Clinical Hospital |
| NCT02025166 | N/A | Jan 1, 2014 | Technion University |
| NCT01718756 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2013 | Mansoura University |
| NCT01480752 | Phase 2 | Sep 1, 2011 | Azad University |
| NCT01069055 | Phase 3 | Feb 1, 2010 | Ankara Yildirim Beyazıt University |
| NCT01117948 | Phase 2 | Sep 1, 2009 | JSW Life Sciences GmbH |
| NCT01564680 | Phase 4 | Mar 1, 2009 | Imam Abdulrahman Bin Faisal University |
| NCT01055470 | N/A | Dec 1, 2008 | Government Medical College, Bhavnagar |
| NCT00997750 | Phase 4 | Mar 1, 2007 | Central Clinical Hospital of Presidential Administration of Russian Federation, Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federati |
| NCT00293657 | Phase 2 | Dec 1, 2005 | Alabama Clinical Therapeutics, California Medical Clinic for Headache, Clinical Research Associates, Inc., Diamond Headache Clinic, Jean Brown Research, Little Rock Family Practice Clinic, Mercy Health Research / Ryan Headache Center, Meridien Research, Michigan Head Pain and Neurological Institute, New England Center for Headache, North Carolina Clinical Research, Northeast Medical Research Associates, Inc., POZEN, Premiere Research Institute, Swedish Pain Center, The Houston Headache Clinic, The Innovative Clinical Research Center, Thomas Jefferson University, University of South Alabama |
| NCT00293631 | Phase 2 | Nov 1, 2005 | Advanced Clinical Research Inc., POZEN |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (32)
32 organizations
Page 1 / 2